Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 24
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Neurourol Urodyn ; 26(4): 495-501, 2007.
Artículo en Inglés | MEDLINE | ID: mdl-17266138

RESUMEN

AIMS: The pelvic floor muscle (PFM) training is effective in alleviating the symptoms of urinary incontinence, but there are very few reports available on its long-term effectiveness. Therefore, 8-year follow-up data have been prospectively analyzed. MATERIALS AND METHODS: Originally 123 women with stress or mixed urinary incontinence participated in an 8-week intensive PFM training program. The training comprised repeated muscle contractions of the pelvic floor and the timely locking of the perineum. An average of 8 years (6-10) had elapsed between the time of present assessment and the completion of the original training. Seventy-nine women were subjected to the present analysis. Self-reported responses of "completely cured" and "more than 50% improved" were regarded as treatment success (TS). An 8-year transition tree and predictive parameters were analyzed. RESULTS: The success rate of the training was 39% at the 8-year follow-up. The transition tree demonstrated that the continence/incontinence status has been varying in 42% of the women, while it was stable in 58% throughout the follow-up period. The 6-year incidence and remission rates of incontinence were 34% and 18%, respectively. The higher pressure difference in the vaginal contraction strength between the baseline and strength at the end of the training is a predictive parameter of the long-term TS. CONCLUSIONS: The results suggest that the 8-year TS rate was 39% and that the altered patterns of the continence status and incidence and remission rates of incontinence were similar to those observed in the general population.


Asunto(s)
Terapia por Ejercicio , Músculo Esquelético/fisiología , Diafragma Pélvico , Incontinencia Urinaria/terapia , Adulto , Anciano , Femenino , Estudios de Seguimiento , Humanos , Persona de Mediana Edad , Perineo/fisiología , Valor Predictivo de las Pruebas , Estudios Prospectivos , Recurrencia , Encuestas y Cuestionarios , Resultado del Tratamiento
2.
Nihon Hinyokika Gakkai Zasshi ; 92(5): 554-9, 2001 Jul.
Artículo en Japonés | MEDLINE | ID: mdl-11517565

RESUMEN

PURPOSE: The usefulness of laparoscopy-assisted total nephroureterectomy for patients with renal pelvic and lower ureteral cancer is evaluated. MATERIAL: Seven patients with renal pelvic cancer and four with lower ureteral cancer performed laparoscopy-assisted total nephroureterectomy from May 1997 to December 2000 (Ten males and one female, mean age 68.5 year-old). METHOD: Of the 11 patients, the initial one received preoperative embolization of the renal artery. Under general anesthesia laparoscopy-assisted total nephroureterectomy underwent via transperitoneal approach in three patients and retroperitoneal approach in eight. After the kidney was completely dissected under laparoscopic procedure, it was delivered en bloc with ureter from the skin incision in the lower abdomen. RESULT: Two patients needed conversion to open surgery. The mean operating time of nine patients except for conversion cases was 272 minutes and the mean blood loss was 313 ml. There was no major complication associated with laparoscopic procedure. There was no significant difference in both complication and recurrence rate between laparoscopy-assisted total nephroureterectomy and open surgery. CONCLUSION: Laparoscopy-assisted total nephroureterectomy is an useful procedure for the treatment of patients with renal pelvic and lower ureteral cancer because it enables us to remove out the kidney and ureter from one small lower abdominal incision.


Asunto(s)
Carcinoma de Células Transicionales/cirugía , Neoplasias Renales/cirugía , Laparoscopía , Nefrectomía/métodos , Uréter/cirugía , Neoplasias Ureterales/cirugía , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Pelvis Renal , Masculino , Persona de Mediana Edad
3.
Chem Pharm Bull (Tokyo) ; 49(1): 54-63, 2001 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-11201226

RESUMEN

Eight cucurbitane-type triterpene glycosides called goyaglycosides-a, -b, -c, -d, -e, -f, -g, and -h and three oleanane-type triterpene saponins termed goyasaponins I, II, and III were isolated from the fresh fruit of Japanese Momordica charantia L. (Cucurbitaceae) together with five known cucurbitane-type triterpene glycosides momordicosides A, C, F1, I, and K. The structures of goyaglycosides and goyasaponins were elucidated on the basis of chemical and physicochemical evidence.


Asunto(s)
Glicósidos/química , Plantas Comestibles/química , Plantas Medicinales/química , Rosales/química , Triterpenos/química , Espectroscopía de Resonancia Magnética , Estructura Molecular , Espectrometría de Masa Bombardeada por Átomos Veloces
4.
Nihon Hinyokika Gakkai Zasshi ; 92(7): 698-701, 2001 Nov.
Artículo en Japonés | MEDLINE | ID: mdl-11766369

RESUMEN

An 82-year old man received total androgen blockade therapy (bilateral orchiectomy and 375 mg/day flutamide) for the treatment of stage C prostate cancer. Serum PSA levels were undetectable for 13 months and thereafter increased gradually. We administered estramustine phosphate sodium (EPS) instead of flutamide under the diagnosis of hormone refractory prostate cancer. EPS therapy was discontinued after 9 months because serum PSA levels increased again. Then, the patient complained of bilateral breast nodules and pain. Bilateral mammectomies were performed due to bilateral breast cancers which had been diagnosed by aspiration biopsies and radiographic examinations, but he died four months after the operations. Final pathological diagnosis was ductal adenocarcinoma of the breasts. Immunohistochemical study revealed expressions of PSA in the breast cancers. We diagnosed double cancers of the prostate and the breast because of the different expression patterns of progesterone receptor between them. We review the literatures and discuss the differential diagnosis of prostate cancer and PSA-producing breast cancer.


Asunto(s)
Adenocarcinoma/tratamiento farmacológico , Antineoplásicos Hormonales/efectos adversos , Neoplasias de la Mama Masculina/etiología , Carcinoma Ductal de Mama/etiología , Estramustina/efectos adversos , Neoplasias de la Próstata/tratamiento farmacológico , Anciano , Anciano de 80 o más Años , Neoplasias de la Mama Masculina/química , Carcinoma Ductal de Mama/química , Humanos , Masculino , Receptores de Progesterona/análisis
5.
Int J Urol ; 7(7): 263-9, 2000 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-10910229

RESUMEN

BACKGROUND: We determined the tumor-associated macrophage (TAM) count to investigate its importance in predicting clinical outcome or prognosis in patients with bladder cancer. METHODS: The TAM count and microvessel count (MVC) were determined immunohistochemically in 63 patients with bladder cancer, including 40 superficial bladder cancers and 23 invasive bladder cancers. To examine the relationship between TAM count and clinical outcome or prognosis in bladder cancer, cystectomy rates, distant metastasis rates, vascular invasion rates and 5 year survival rates were compared between patients with low (< 67) and high (> or = 67) TAM counts. RESULTS: The TAM count in invasive bladder cancers (154.22+/-11.98) was significantly higher than in superficial bladder cancers (49.05+/-7.76; P<0.0001). The MVC in invasive bladder cancers (71.55+/-10.44) was also significantly higher than in superficial bladder cancers (47.02+/-5.57; P<0.05). There was a positive correlation between TAM count and MVC (r=0.30; P=0.02). Immunohistochemical staining using CD68/horseradish peroxidase monoclonal antibody showed more infiltrating cells in invasive than superficial bladder cancers. Patients with a high TAM count (> or =67) showed significantly higher rates of cystectomy, distant metastasis and vascular invasion than those with a lower TAM count (<67). The 5 year survival rate estimated using the Kaplan-Meier method was significantly lower in patients with a high TAM count than in those with a low TAM count (P<0.0001). CONCLUSIONS: Our results suggest that determination of TAM count in bladder cancer tissues is of value to predict the clinical outcome or prognosis and to select appropriate treatment strategies in patients with bladder cancer.


Asunto(s)
Macrófagos , Neoplasias de la Vejiga Urinaria/mortalidad , Neoplasias de la Vejiga Urinaria/patología , Adulto , Anciano , Anciano de 80 o más Años , Recuento de Células , Femenino , Humanos , Masculino , Microcirculación , Persona de Mediana Edad , Pronóstico , Tasa de Supervivencia , Neoplasias de la Vejiga Urinaria/irrigación sanguínea
6.
Int J Urol ; 7(2): 35-40, 2000 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-10710245

RESUMEN

BACKGROUND: Prediction of the extent of calcium supplement will facilitate safe and efficient management of hypocalcemia in the early postoperative stage of total parathyroidectomy with autotransplantation (PTXa) in patients with renal osteodystrophy. METHODS: The correlation between the extent of calcium deficiency, estimated by the amount of calcium supplement over 48 h after PTXa and using various parameters such as carboxy terminal parathyroid hormone (c-PTH), intact PTH (i-PTH), alkaline phosphatase (ALP), serum calcium, serum phosphorus, duration of hemodialysis, total weight of resected parathyroid glands and degree of subperiosteal resorption of the middle phalanx was examined in 49 patients who underwent PTX with subcutaneous autotransplantation. Bone mineral density (BMD) was also determined before, 3 months and 1 year after PTXa with dual energy X-ray absorptiometry (DEXA) in 13 patients. RESULTS: There was a positive correlation between pre-operative i-PTH level (r=0.56, P<0.0005) or ALP level (r=0.50, P<0.0005) and the amount of calcium supplement over 48 h after PTXa in these patients. Furthermore, the degree of subperiosteal resorption, determined by Jensen's classification, was significantly correlated with the amount of calcium supplement after PTX (P<0.05). Bone mineral density 3 months after (P<0.0005) and 1 year after PTXa (P<0.001) significantly increased compared with BMD before PTXa in all patients examined. CONCLUSION: These findings suggest that the pre-operative determination of i-PTH, ALP levels and degree of subperiosteal resorption allow the management of hypocalcemia safely and efficiently in renal osteodystrophy patients after PTXa.


Asunto(s)
Gluconato de Calcio/uso terapéutico , Trastorno Mineral y Óseo Asociado a la Enfermedad Renal Crónica/cirugía , Hipocalcemia/tratamiento farmacológico , Paratiroidectomía , Complicaciones Posoperatorias/tratamiento farmacológico , Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad
7.
EMBO J ; 18(23): 6642-52, 1999 Dec 01.
Artículo en Inglés | MEDLINE | ID: mdl-10581238

RESUMEN

The ATP-bound but not the ADP-bound form of DnaA protein is active for replication initiation at the Escherichia coli chromosomal origin. The hydrolysis of ATP bound to DnaA is accelerated by the sliding clamp of DNA polymerase III loaded on DNA. Using a culture of randomly dividing cells, we now have evidence that the cellular level of ATP-DnaA is repressed to only approximately 20% of the total DnaA molecules, in a manner depending on DNA replication. In a synchronized culture, the ATP-DnaA level showed oscillation that has a temporal increase around the time of initiation, and decreases rapidly after initiation. Production of ATP-DnaA depended on concomitant protein synthesis, but not on SOS response, Dam or SeqA. Regeneration of ATP-DnaA from ADP-DnaA was also observed. These results indicate that the nucleotide form shifts of DnaA are tightly linked with an epistatic cell cycle event and with the chromosomal replication system.


Asunto(s)
Adenina/química , Adenosina Trifosfato/metabolismo , Proteínas Bacterianas/biosíntesis , Proteínas de Unión al ADN/biosíntesis , ADN Polimerasa Dirigida por ADN , Escherichia coli/química , Factores de Transcripción , Adenosina Difosfato/metabolismo , Proteínas de la Membrana Bacteriana Externa , Proteínas Bacterianas/química , Proteínas Bacterianas/metabolismo , Ciclo Celular , Replicación del ADN , Proteínas de Unión al ADN/química , Relación Dosis-Respuesta a Droga , Escherichia coli/metabolismo , Proteínas de Escherichia coli , Hidrólisis , Pruebas de Precipitina , Unión Proteica , Origen de Réplica , Temperatura , Factores de Tiempo
8.
Urology ; 54(5): 829-33, 1999 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-10565742

RESUMEN

OBJECTIVES: To assess the value of magnetic resonance imaging (MRI) for predicting the alpha-blocker response in men with symptomatic benign prostatic hyperplasia (BPH) and to examine the relationship between MRI and the area density of smooth muscle cells in BPH. METHODS: Twenty-eight men were consecutively enrolled in this study and received tamsulosin 0.2 mg once daily for 4 to 6 weeks. The efficacy of tamsulosin was determined by measuring improvements in the maximum urinary flow rate (Qmax) and International Prostate Symptom Score (IPSS). The patients underwent T2-weighted MRI and were separated into a high (H) or iso-low (IL) group according to the signal intensity of the inner gland of the prostate compared with that of bone marrow of the proximal femur head. The area density of smooth muscle cells was determined using immunostaining with antiactin antibody in 16 prostate specimens. RESULTS: IPSS significantly decreased after the administration of tamsulosin from 16 +/- 1 to 8 +/- 1 (n = 28, P <0.0001 ), and 76.7% of the patients had an improved IPSS of 25% or greater. Qmax was significantly increased in group IL (P = 0.03) but not in group H. Of the patients in group IL, 53.3% had a Qmax response (an increase of Qmax of 30% or more); 15.4% did so in group H (P = 0.04). The area density of smooth muscle cells was 48.1 +/- 3.7% in group IL (n = 9) and 36.7 +/- 3.2% in group H (n = 7, P = 0.04). CONCLUSIONS: MRI is useful in estimating the area density of smooth muscle cells in the prostate and in predicting Qmax response for alpha-blocker therapy in patients with symptomatic BPH.


Asunto(s)
Antagonistas Adrenérgicos alfa/uso terapéutico , Imagen por Resonancia Magnética , Hiperplasia Prostática/tratamiento farmacológico , Hiperplasia Prostática/patología , Sulfonamidas/uso terapéutico , Anciano , Humanos , Masculino , Valor Predictivo de las Pruebas , Hiperplasia Prostática/fisiopatología , Tamsulosina , Urodinámica
9.
Nihon Hinyokika Gakkai Zasshi ; 90(12): 906-10, 1999 Dec.
Artículo en Japonés | MEDLINE | ID: mdl-10658462

RESUMEN

PURPOSE: To evaluate the usefulness of transperitoneal anterior approach in laparoscopic radical nephrectomy for patients with renal cell carcinoma. MATERIAL: Ten patients (Eight males and two females) with small renal cell carcinoma less than 7 cm in diameter were treated with laparoscopic radical nephrectomy between June 1997 and May 1999. Clinical stage was T1aN0M0 in 6 cases and T1bN0M0 in 4 cases. METHOD: Of the 10 patients, the initial four received preoperative embolization of the renal artery. Under general anesthesia laparoscopic radical nephrectomy via transperitoneal anterior approach was performed in all patients. This procedure facilitates initiated early access to the renal vessels as does open radical nephrectomy. The kidney was dissected en bloc with Gerota's fascia and delivered from the small skin incision without morcellation. RESULT: Two patients needed conversion to open surgery. The mean operating time of eight patients except for conversion cases was 247 minutes and the mean blood loss was 258 ml. There was no major complication associated with laparoscopic procedure. CONCLUSION: Transperitoneal anterior approach in laparoscopic radical nephrectomy is a suitable and useful procedure for the treatment of small renal cell carcinoma because it enables us to avoid possible tumor manipulation by early access to the renal vessels as open radical nephrectomy.


Asunto(s)
Carcinoma de Células Renales/cirugía , Neoplasias Renales/cirugía , Laparoscopía , Nefrectomía/métodos , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Resultado del Tratamiento
10.
Br J Urol ; 79(5): 681-7, 1997 May.
Artículo en Inglés | MEDLINE | ID: mdl-9158500

RESUMEN

OBJECTIVE: To investigate the role of vascular endothelial growth factor (VEGF) in tumour angiogenesis in renal cell carcinoma (RCC). MATERIALS AND METHODS: The expression of VEGF was examined in tissue samples from 25 patients with RCC using the reverse-transcriptase polymerase chain reaction (RT-PCR). Cellular localization of VEGF was studied in normal kidney and RCC tissues. Tube formation by human omental microvascular endothelial (HOME) cells co-cultured with A498 RCC cells was quantified in a three-dimensional collagen gel using computer-image analysis. RESULTS: RT-PCR detected VEGF m-RNA in tissue from 20 of 25 patients with RCC. An immunohistochemical study revealed that VEGF was primarily localized in the cytosol of normal renal tubule cells and RCC cells. Tube formation by HOME cells was increased in the presence of A498 cells overexpressing VEGF mRNA, induced by exogenous VEGF in a dose-dependent manner and completely inhibited by an anti-VEGF antibody. CONCLUSION: VEGF, which is produced and released from RCC cells, may elicit tumour angiogenesis by inducing microvessel tubulogenesis in patients with RCC. The co-culture system may be useful for screening inhibitors of tumour angiogenesis in RCC.


Asunto(s)
Carcinoma de Células Renales/irrigación sanguínea , Factores de Crecimiento Endotelial/fisiología , Endotelio Vascular/fisiología , Neoplasias Renales/irrigación sanguínea , Linfocinas/fisiología , Neovascularización Patológica , Northern Blotting , Carcinoma de Células Renales/metabolismo , Factores de Crecimiento Endotelial/genética , Humanos , Inmunohistoquímica , Neoplasias Renales/metabolismo , Linfocinas/genética , Microcirculación , Reacción en Cadena de la Polimerasa , ARN Mensajero/metabolismo , Células Tumorales Cultivadas , Factor A de Crecimiento Endotelial Vascular , Factores de Crecimiento Endotelial Vascular
11.
J Urol ; 157(4): 1260-4; discussion 1264-5, 1997 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-9120915

RESUMEN

PURPOSE: The clinical significance of multi-drug resistant proteins, such as multi-drug resistance associated protein and P-glycoprotein, in terms of prognostic value was determined in patients with bladder cancer. MATERIALS AND METHODS: The expression of multi-drug resistance associated protein and P-glycoprotein was investigated immunohistochemically before and after chemotherapy. The relationship between expression of these multi-drug resistant proteins and clinical outcome assessed by tumor recurrence rate, cystectomy rate and 5-year survival rate was also investigated in 33 patients with bladder cancer. RESULTS: Before chemotherapy multi-drug resistance associated protein expression was observed in 1 of 28 patients (4%) while P-glycoprotein expression was observed in 22 of 33 (67%). Multi-drug resistance associated protein induction by chemotherapy was observed in 6 of 28 patients (21%), whereas P-glycoprotein induction was noted in 4 (14%). Multi-drug resistance associated protein in this disease is induced more frequently by high dose (more than 300 mg.) than low dose (less than 300 mg.) anthracyclines (p < 0.01). Immunohistochemical analysis also revealed co-expression of multi-drug resistance associated protein and P-glycoprotein in 5 of 28 patients (18%) after chemotherapy. However, there was no significant correlation between positive P-glycoprotein expression before chemotherapy and clinical outcome. CONCLUSIONS: Multi-drug resistance associated protein as well as P-glycoprotein mediated multi-drug resistance may be induced after chemotherapy for bladder tumors. However, the presence of P-glycoprotein before chemotherapy does not predict clinical outcome in patients with bladder cancer.


Asunto(s)
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/biosíntesis , Transportadoras de Casetes de Unión a ATP/biosíntesis , Proteínas de Neoplasias/biosíntesis , Neoplasias de la Vejiga Urinaria/metabolismo , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/análisis , Transportadoras de Casetes de Unión a ATP/análisis , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Estudios de Seguimiento , Humanos , Inmunohistoquímica , Masculino , Persona de Mediana Edad , Proteínas Asociadas a Resistencia a Múltiples Medicamentos , Proteínas de Neoplasias/análisis , Pronóstico , Neoplasias de la Vejiga Urinaria/química , Neoplasias de la Vejiga Urinaria/tratamiento farmacológico
12.
J Urol ; 157(2): 699-703, 1997 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-8996401

RESUMEN

PURPOSE: To investigate the role of basic fibroblast growth factor (b-FGF) in angiogenesis in renal cell carcinoma. MATERIALS AND METHODS: We examined b-FGF expression in 25 patients with renal cell carcinoma (RCC) by reverse transcriptase polymerase chain reaction (RT-PCR). We measured the tube formation by human omental microvascular endothelial (HOME) cells induced by b-FGF in a three-dimensional collagen gel in the absence or presence of SN12C human renal cancer cells by means of computer-image analysis. RESULTS: RT-PCR analysis detected b-FGF m-RNA in 20 (80%) of 25 patients with RCC. The tube formation of HOME cells was increased in the presence of SN12C cells overexpressing b-FGF mRNA, induced by exogenous b-FGF in a dose dependent manner and completely inhibited by anti-b-FGF antibody. CONCLUSIONS: Basic-FGF may develop tumor angiogenesis by inducing microvessel tubulogenesis in patients with RCC.


Asunto(s)
Carcinoma de Células Renales/irrigación sanguínea , Endotelio Vascular/patología , Factor 2 de Crecimiento de Fibroblastos/fisiología , Neoplasias Renales/irrigación sanguínea , Neoplasias Renales/metabolismo , Neovascularización Patológica , Adulto , Anciano , Anciano de 80 o más Años , Capilares/patología , Regulación Neoplásica de la Expresión Génica , Humanos , Persona de Mediana Edad , Células Tumorales Cultivadas
13.
Int J Urol ; 4(6): 591-6, 1997 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-9477190

RESUMEN

BACKGROUND: The purpose of this study was to evaluate the muscarinic receptor subtypes expressed in rat bladder smooth muscle and characterize the muscarinic receptor-coupled phosphatidylinositol (PI) hydrolysis in order to clarify the first step of bladder smooth muscle contraction. METHODS: Expressions of mRNAs of muscarinic receptor subtypes were examined by Northern blot analysis. Changes in the mass of inositol 1,4,5-trisphosphate (IP3) and the inhibitory effects of muscarinic subtype specific antagonists on PI hydrolysis were determined after carbachol stimulation. RESULTS: mRNAs of m2 and m3 genes, encoding M2 and M3 receptors, were expressed in rat bladder smooth muscle. Carbachol produced a rapid increase of IP3, which returned to the basal level within 30 seconds. 4-Diphenylacetoxyl-N-methylpiperidine methiodide (4-DAMP; M1 and M3 antagonist) strongly inhibited the PI hydrolysis, but methoctramine (M2 antagonist) partially inhibited it at 10(-4) mol/L. The IC50 value for atropine was 9.5 x 10(-9) mol/L, for pirenzepine 6.4 x 10(-6) mol/L, and for 4-DAMP 1.5 x 10(-7) mol/L. CONCLUSION: M2 and M3 receptors are expressed in rat urinary bladder. Only M3 receptor was involved in the production of IP3, which might induce the initial phase of contractile response in rat bladder smooth muscle after carbachol stimulation.


Asunto(s)
Músculo Liso/metabolismo , Fosfatidilinositoles/metabolismo , ARN Mensajero/metabolismo , Receptores Muscarínicos/metabolismo , Vejiga Urinaria/metabolismo , Animales , Northern Blotting , Cartilla de ADN/química , Expresión Génica , Hidrólisis , Inositol 1,4,5-Trifosfato/metabolismo , Masculino , Agonistas Muscarínicos/farmacología , Antagonistas Muscarínicos/farmacología , Contracción Muscular/fisiología , Músculo Liso/efectos de los fármacos , Ratas , Ratas Sprague-Dawley , Receptores Muscarínicos/genética , Vejiga Urinaria/citología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA